Nabota’s quality control process is a rigorous, multi‑stage system that makes sure every single batch of the botulinum toxin type‑A product meets strict safety, potency, and purity specifications from raw material intake all the way through final release.
End‑to‑End QC Pipeline at a Glance
To keep the process transparent and scientifically sound, the manufacturer groups its quality checks into distinct stages. Each stage is equipped with defined tests, acceptance limits, and documentation requirements that together form a closed‑loop quality chain.
| Stage | Key Test(s) | Typical Method | Acceptance Criteria (Nabota 100 IU) |
|---|---|---|---|
| Raw Material Control | Identity, purity, endotoxin, sterility | PCR for DNA identity, LAL assay for endotoxin, membrane‑filtration sterility test | Identity confirmed; endotoxin ≤0.5 EU/vial; sterility negative |
| Cell Bank & Fermentation | Cell viability, productivity, mycoplasma, adventitious agents | Short‑tandem repeat (STR) profiling, flow cytometry, PCR for mycoplasma | ≥90 % viability; no mycoplasma detected; productivity ≥1.0 × 10⁶ IU per batch |
| Harvest & Primary Purification | Total protein, host‑cell protein (HCP), residual DNA | Bradford assay, ELISA for HCP, qPCR for DNA | HCP ≤5 ppm; residual DNA ≤10 pg per dose |
| Polishing & Formulation | Neurotoxin concentration, pH, osmolality, moisture | HPLC for potency, pH meter, vapor‑pressure osmometer, Karl Fischer titration | Potency 95–115 IU/vial; pH 6.8–7.2; osmolality 280–320 mOsm/kg; moisture ≤3 % |
| Fill‑Finish & Packaging | Visual inspection, weight uniformity, seal integrity | Automated vision system, gravimetric check, leak test | 100 % visual pass; fill weight 4.5 g ± 0.2 g; no leaks |
| Release Testing | Potency (mouse LD₅₀), sterility, endotoxin, stability, particle count | In vivo potency assay, USP <71> sterility, LAL, accelerated stability study, light obscuration | Potency 95–115 IU; sterility negative; endotoxin ≤0.5 EU; ≥90 % potency retained after 24 mo at 2–8 °C; no visible particles |
Raw Material Control – The First Line of Defense
Every incoming ingredient, from the bacterial seed stock to the stabilizers, undergoes a battery of identity and safety checks. The most critical raw material is the clostridial neurotoxin‑producing strain, which is verified by:
- PCR amplification of the toxin gene – confirms the presence of the correct neurotoxin gene cluster.
- Sequencing of the 16S rRNA region – ensures strain authenticity.
- Endotoxin screening using a kinetic chromogenic LAL assay – any batch exceeding 0.5 EU per vial is rejected.
- Sterility testing via membrane filtration – no microbial growth after 14 days of incubation.
These tests are performed in duplicate, and results are entered into the electronic batch record (EBR) within 24 hours of receipt.
“GMP guidelines require that each step of the manufacturing process be documented and verified, ensuring traceability and accountability.” — EU GMP Annex 1, 2022
Cell Bank & Fermentation – Building the Production Engine
The manufacturer maintains a two‑tiered cell bank system: a Master Cell Bank (MCB) and a Working Cell Bank (WCB). Each bank is characterized by:
- Short‑tandem repeat (STR) profiling – a DNA fingerprint that matches the reference strain.
- Growth kinetics in a 5 L bioreactor – measured every 2 hours for pH, dissolved oxygen (DO), temperature, and glucose consumption.
- Productivity assays at three time points (mid‑log, late‑log, stationary) – yields are plotted to determine optimal harvest time.
- Adventitious agent testing in accordance with ICH Q5A – includes in‑vitro and in‑vivo tests, as well as PCR for specific viruses.
The fermentation process runs under tightly controlled conditions: temperature 37 °C ± 0.5 °C, pH 6.8 ± 0.1, DO ≥ 30 % saturation. Harvest typically occurs 12 hours after the DO curve peaks, delivering a raw neurotoxin titer of ≈1.2 × 10⁶ IU / L.
Purification – From Crude Extract to High‑Purity Neurotoxin
Primary purification employs a series of chromatographic steps designed to separate the neurotoxin from host‑cell proteins, nucleic acids, and residual media components. The typical purification train includes:
- Immobilized metal affinity chromatography (IMAC) – captures His‑tagged neurotoxin fragments.
- Ion‑exchange chromatography (IEX) – removes bulk impurities based on charge.
- Size‑exclusion chromatography (SEC) – polishes the product, reducing aggregates to ≤1 %.
Residual impurity limits are strict: host‑cell protein ≤5 ppm, residual DNA ≤10 pg per dose, and residual detergent (Tween‑80) ≤0.1 % w/w. Each purification step is monitored with real‑time UV absorbance and conductivity sensors, and any deviation automatically triggers a deviation report.